Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update.

Although the mortality from cardiovascular disease has declined, it remains the leading cause of morbidity and mortality in the United States. Dyslipidemia is a modifiable risk factor that plays a significant role in the development of atherosclerotic cardiovascular disease. Treating dyslipidemia by lowering cholesterol, predominately low-density lipoprotein cholesterol, has been shown to reduce cardiovascular events.

Frequency of "on-label" use of intravenous diltiazem for rate control in patients with acute-onset atrial fibrillation or atrial flutter.

Purpose: The study was designed to characterize "on-label" use of i.v. diltiazem in patients with acute atrial fibrillation or flutter (AFF).

Impact of Clinical Pharmacist Interventions on 30-Day Readmission Rate in Hospitalized Patients With Acute Myocardial Infarction.

: Limited literature exists on the positive impact of pharmacists specifically on hospital readmission of patients with acute myocardial infarction (AMI). : To evaluate the overall effect of clinical pharmacist interventions on preventing hospital readmissions and improving the health of patients with AMI. Secondary objectives include identifying trends in the demographic characteristics of AMI patients, identifying potential barriers to adherence, and assessing the average time spent by a pharmacist counseling AMI patients.